On October 1, Canadian Space Agency (CSA) astronaut Joshua Kutyrk is set to launch from Cape Canaveral, Florida, taking along innovative Canadian technology. Living and working in space poses various risks due to the body’s adaptation to low gravity, including the potential development of dangerous blood clots. To address this concern, NASA is focused on ensuring the safety of astronauts aboard the space station.
Mathieu Caron, director of CSA’s astronaut office, highlighted the importance of understanding the risks associated with prolonged space travel and the formation of blood clots. To address this, NASA has partnered with Vancouver-based Response Biomedical to implement advanced technology for monitoring astronaut health.
One key instrument, known as Acute Care Testing in Space (ACTIS), can detect the presence of D-dimer in blood, a protein fragment indicative of blood clots. This technology, derived from Response Biomedical’s RAMP platform, offers rapid and efficient blood testing capabilities for various conditions, including blood clots, heart attacks, and infectious diseases like COVID-19.
The portable nature of the ACTIS device allows for quick test results, making it a valuable tool for space missions and remote communities on Earth where timely diagnosis is crucial. Taso Tsonis, CEO of Response Biomedical, emphasized the significance of this Canadian-developed technology being utilized both in space and on Earth to enhance healthcare accessibility.
The potential success of ACTIS on the International Space Station opens doors for its application in future space exploration missions, reflecting Canada’s innovation and expertise in health and life sciences research. The collaboration between NASA and CSA signifies a significant milestone for Canadian technology, showcasing its adaptability and long-term value in advancing healthcare solutions.